■ Salvat Laboratories announced submission of its NDA for the first ocular corticosteroid formulated in a nanoemulsion to treat inflammation and pain in post–ocular surgery patients. This submission is supported by 2 phase 3 clinical trials testing the corticosteroid nanoemulsion clobetasol in more than 400 US subjects from 40 centers, according to a company news release. The company’s patented drug delivery technology, IMPACT-SVT, improves drug penetration and bioadhesion, “providing excellent comfort,” according to a news release.

The company stated that this “superpotent” corticosteroid has never been used before as eye drops. Its packaging in single-dose vials offers superior advantages over other established alternatives, it has been shown safe and effective, and it has very little effect on IOP.